[ad_1]
Jeddah SPA
According to media and communication platforms, the Ministry of Health has denied the health status associated with Vitrakvi drug and the elimination of cancer.
"Vitrakvi is the brand name of Larotrectinib, which does not treat cancer completely or completely, as recently mentioned on social networking sites, but aims to control the growth of cancer and its spread for as long as possible, and "It's not an alternative," the ministry said. For surgical, chemical and radiological treatment.
In the first and second phase, the study included 55 cancer patients and carriers of the TRK gene mutation, with a full response rate of 13% and a partial response rate of 62%, a response that did not last long in all patients. Study participants continued to respond to 39% of patients after the first year of treatment.
Source link
